Amina Rafique, MD
Pediatric Hematology-Oncology · Orlando, FLNPI 1518197086
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. CSL Behring accounts for 67.4% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $6,040 and has fallen 97.8% since, to $135 in 2025.
Across 52 payments — averaging $208.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$7K
- HEMA Biologics, LLC$3K
- Shire North American Group Inc$273
- Sanofi$100
- Novo Nordisk$88
- Genentech USA, Inc.$88
- plus $469 from 16 others
Across 13 payments — averaging $9174.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$50K
- Global Blood Therapeutics, Inc.$28K
- Bayer$23K
- Octapharma USA, Inc.$16K
- HEMA Biologics, LLC$2K
What the payments were for
- Consulting fees$2,50023%
- Speaking & faculty fees$6,10556%
- Travel & lodging$9919%
- Food & beverage$1,11710%
- Education$1111%
- Gifts$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 10 | $7,303 |
| HEMA Biologics, LLC | 6 | $2,515 |
| Shire North American Group Inc | 5 | $273 |
| Sanofi | 3 | $100 |
| Novo Nordisk | 3 | $88 |
| Genentech USA, Inc. | 3 | $88 |
| Sobi, Inc | 4 | $86 |
| Genentech, Inc. | 1 | $72 |
| Novartis | 3 | $62 |
| Eurofins Viracor, LLC | 1 | $36 |
| Emmaus Medical, Inc. | 2 | $29 |
| Amgen | 1 | $23 |
| Biomarin Pharmaceutical Inc. | 1 | $22 |
| Global Blood Therapeutics, Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| AstraZeneca | 1 | $17 |
| Pfizer | 1 | $17 |
| Medexus Pharma, Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Tesaro, Inc. | 1 | $12 |
| Dova Pharmaceuticals | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SevenFact$2,500
How this compares
$10,836 in reported general payments places this provider in the 85th percentile of 132 pediatric hematology-oncology providers in Florida.
See all pediatric hematology-oncology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxbrytaVoxelotor | 18 | $208,118 |
| EliquisApixaban | 20 | $12,799 |
| Deferasirox | 15 | $8,867 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 28 | $5,528 |
| Hydroxyurea | 47 | $1,500 |
| Oxycodone Hcl | 65 | $419 |
| Gabapentin | 19 | $146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Global Blood Therapeutics, Inc.Oxbryta | $19 | $208,11818 claims |
| PfizerEliquis | $17 | $12,79920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 132 pediatric hematology-oncology providers in Florida.
Other pediatric hematology-oncology in Orlando
- Shveta GuptaOrlando$714K
- Jaime Libes-BanderOrlando$133K
- Dennis Borrero RamosOrlando$56K
- Amy SmithOrlando$45K
- Fouad HajjarOrlando$21K
- Brian TulliusOrlando$5K
- Robert SutphinOrlando$1K
- Christian Nieves RiveraOrlando$1K
- Vincent GiustiOrlando$712
- Guillermo DeanguloMiami$929K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.